ClinicalTrials.gg
WithdrawnNCT04086212Updated Oct 1, 2024

Ultrafiltration Efficacy of a PD Solution Containing Icodextrin-Xylitol-Carnitine

A Phase 2 interventional study of Icodextrin, xylitol and carnitine solution for peritoneal dialysis and EXTRANEAL 7.5G/100Ml Peritoneal Dialysis Solution in End Stage Renal Disease (ESRD), sponsored by Iperboreal Pharma Srl. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Iperboreal Pharma Srl · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
The study never started

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Randomized, cross-over, controlled, open label study. The aim of this study is to demonstrate that glucose may completely be replaced by a combination of xylitol and carnitine in the bimodal PD solution for long dwell exchange.

Read the detailed description

The use of a solution icodextrin, xylitol and carnitine (IXC) as the osmotic agent in dialysate for the long dwell exchange provides sustained ultrafiltration (UF) through colloid osmosis, allowing a consistent reduction in extracellular fluid volume without the expected fall in urine output. The other major advantage of IXC is the reduced exposure and absorption of glucose as the main osmotic agent in PD therapy. The aim of this study is to demonstrate that glucose may completely be replaced by a combination of xylitol and carnitine in the bimodal IXC-based PD solution. Compared to glucose, indeed, carnitine and xylitol are extremely stable naturally occurring compounds, even at temperatures higher than those used to steam-sterilize infusional product. As a consequence, xylitol and carnitine may represent better alternatives than glucose as an osmotic ingredient both from the manufacturing and biocompatibility standpoints. Moreover, xylitol and carnitine have an excellent safety profile and possess distinct systemic actions, which are more favorable than glucose.

02

Conditions studied

  • End Stage Renal Disease (ESRD)
03

In context

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Lead sponsor

Iperboreal Pharma Srl is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Diagnosis of ESRD and have been on Continuous Ambulatory Peritoneal Dialysis (CAPD) or Automated Peritoneal Dialysis (APD) for at least 3 months
  • A stable clinical condition during the two weeks immediately prior to randomization
  • Blood concentration above 8,5 g/100ml
  • Has not experienced peritonitis episodes in the last 3 months
  • Treated with Extraneal for at least 1 month
  • Peritoneal Equilibration Test (PET) performed in the last three months
  • Has understood and signed the Form.

Exclusion criteria

Exclusion Criteria:

  • History of drug or alcohol abuse in the six months prior to entering the protocol
  • Acute infectious condition
  • History of severe congestive heart failure and arrhythmia
  • within the past 5 years, including lymphoproliferative disorders
  • A medical condition that, in the judgment of the Investigator, would jeopardize the patient's safety following exposure to study drug
  • A clinically relevant under-hydration as judged by the treating physician
  • History of L-Carnitine therapy or use in the month before entering the study
  • Received any drug in the 3 months before entering the study
  • Pregnancy, lactation, fertility age without protection against pregnancy by adequate measures
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    IXC Peritoneal dialysis solution

    IXC (Icodextrin, Xylitol and L-Carnitine) Peritoneal dialysis solution

    Drug: Icodextrin, xylitol and carnitine solution for peritoneal dialysis

  • Active comparator
    Icodextrin

    Extraneal® (7.5% Icodextrin) Peritoneal dialysis solution

    Drug: EXTRANEAL 7.5G/100Ml Peritoneal Dialysis Solution

Interventions

  • DrugIcodextrin, xylitol and carnitine solution for peritoneal dialysis

    Patients will receive a long dwell exchange for three days.

    Also known as: IXC

  • DrugEXTRANEAL 7.5G/100Ml Peritoneal Dialysis Solution

    Drug page: IcodextrinStudies of IcodextrinIcodextrin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive a long dwell exchange for three days.

    Also known as: icodextrin

06

What researchers measure

Primary outcomes

  1. Net-ultrafiltration

    Net Ultrafiltration at 10 hours (duration of long dwell), in mL, is defined as the difference between the weight of drained volume and weight of the effluent (fill volume).

    Time frame: Changes from baseline value at the end of each product administration period (3 days)

Secondary outcomes

  1. Sodium removal

    Net sodium removal will be calculated as the difference between the total amount of sodium drained at end of long dwell (10 hours) and its measure value in the dialysate at time 0 before the initial infusion. Sodium will determined by the hospital laboratory.

    Time frame: Calculated every day for 3 days during each product administration period.

  2. Carnitine plasmatic level

    Carnitine plasmatic level is assessed by chemical analysis of patient's plasma samples.

    Time frame: Every day for 3 days during each product administration and during the wash-out period

  3. Xylitol plasmatic level

    Xylitol plasmatic leve is assessed by chemical analysis of patient's plasma samples.

    Time frame: Every day for 3 days during each product administration and during the wash-out period.

  4. Xylitol absorption

    Xilitol absorption is determined by calculating the difference (in grams) between the amount of xylitol (measured by lab analysis) in plasma and the amount of xylitol in the patient's dialysis solution administered.

    Time frame: Every day for 3 days during each product administration

  5. Adverse Events

    Time frame: Through study completion, an average of 21 days.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2019 (actual). Primary completion is estimated for Dec 2022, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2019
First posted
Sep 11, 2019
StartActual
Oct 2, 2019
Primary completionEst.
Dec 2022
CompletionEst.
Apr 2023
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04086212
Lead sponsor
Iperboreal Pharma Srl
Responsible party
Sponsor
First posted
Sep 11, 2019
Start date
Oct 2, 2019
Primary completion
Dec 2022 (estimated)
Completion
Apr 2023 (estimated)
Last update
Oct 1, 2024

Study contacts

Mario Bonomini, MD
principal investigator · Institute of Nephrology, University of Chieti, Italy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion